- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock | 1 | Investing.com | ||
| 22.05. | Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent-Aktie | 1 | Investing.com Deutsch | ||
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 22.05. | Cantor Fitzgerald reiterates Overweight rating on ArriVent stock | 1 | Investing.com | ||
| 11.05. | ArriVent BioPharma GAAP EPS of -$0.96 misses by $0.10 | 1 | Seeking Alpha | ||
| 11.05. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | 2.785 | GlobeNewswire (Europe) | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| 11.05. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | ArriVent BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | ArriVent BioPharma, Inc.: ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers | 367 | GlobeNewswire (Europe) | Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of... ► Artikel lesen | |
| 17.03. | ArriVent BioPharma, Inc.: ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 17.03. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | ArriVent Biopharma, Inc. Full Year Loss Increases | 1 | RTTNews | ||
| 05.03. | ArriVent BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 05.03. | ArriVent BioPharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald | 5 | Investing.com | ||
| 16.01. | Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent | - | Investing.com Deutsch | ||
| 06.01. | ArriVent BioPharma: Oppenheimer bestätigt "Outperform"-Rating und Kursziel von 44 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.01. | Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock | 1 | Investing.com | ||
| 22.12.25 | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | 479 | GlobeNewswire (Europe) | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,370 | +1,28 % | BIOFRONTERA AG zeigt strukturelle Stärke | ||
| BIONXT SOLUTIONS | 0,210 | -4,55 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,112 | -0,81 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,950 | +1,02 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 69,74 | -0,66 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| ATAIBECKLEY | 3,540 | -1,67 % | Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003's Phase 3 Readiness | ||
| ALDEYRA | 1,820 | +2,25 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| ADAPTIVE BIOTECHNOLOGIES | 15,450 | +2,05 % | Adaptive Biotechnologies Corp - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 4,920 | -0,71 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| BIOMERIEUX | 66,50 | +0,38 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| AC IMMUNE | 2,155 | 0,00 % | AC Immune SA: AC Immune First Quarter 2026 Financial and Corporate Updates | AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers... ► Artikel lesen | |
| 10X GENOMICS | 28,390 | +1,41 % | 10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics | ||
| AGIOS | 31,200 | 0,00 % | AGIOS PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BIOXCEL THERAPEUTICS | 1,150 | +2,68 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| AGENUS | 2,680 | -1,47 % | AGENUS INC - 8-K, Current Report |
Das Unternehmen ARRIVENT BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 33,740 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.